Actavis UK Ltd v. Eli Lilly and Company Ltd

Actavis UK Ltd v. Eli Lilly and Company Ltd
Case name	Actavis UK Ltd v. Eli Lilly and Company Ltd
Court	Supreme Court of the United Kingdom
Date decided	2017
Citation	[2017] UKSC 48
Judges	Lord Neuberger, Lord Sumption, Lady Hale, Lord Carnwath, Lord Toulson
Keywords	patent law, infringement, doctrine of equivalents, claim construction

Actavis UK Ltd v. Eli Lilly and Company Ltd Actavis UK Ltd v. Eli Lilly and Company Ltd was a landmark decision of the Supreme Court of the United Kingdom that reformulated patent infringement principles by endorsing a modified doctrine of equivalents and altering traditional claim construction approaches. The ruling intervened in longstanding debates involving patent holders such as Eli Lilly and Company, generic manufacturers including Actavis UK Ltd, and regulatory frameworks like the European Patent Convention and United Kingdom Patents Act 1977. The judgment influenced jurisprudence in jurisdictions such as United States, Germany, France, and European Union institutions including the Court of Justice of the European Union.

Background

The dispute arose against a backdrop of controversies over patent scope disputes similar to cases involving Pfizer, Novartis, GlaxoSmithKline, and Roche. Debates mirrored doctrinal shifts following decisions by courts such as the House of Lords in earlier patent cases and contrasted with approaches in Federal Circuit jurisprudence in the United States Court of Appeals for the Federal Circuit. The industry context involved pharmaceutical regulatory regimes administered by agencies like the Medicines and Healthcare products Regulatory Agency and market actors including Generic drug manufacturers and multinational research firms represented at trial by firms with histories in cases involving patent pools and licensing disputes.

Facts of the Case

Eli Lilly owned patents covering the active ingredient tadalafil, linked to the European Medicines Agency approvals and marketed treatments by companies akin to Eli Lilly and Company and other patentees. Actavis sought to market a generic alternative, prompting assertions of patent infringement under provisions of the Patents Act 1977. The factual matrix involved comparisons to prior art exemplified by references to documents similar to those considered in disputes such as Merck Sharp & Dohme litigation and technical evidence presented by experts with backgrounds tied to institutions like University of Oxford and University of Cambridge. Procedural history included decisions from the High Court of Justice (England and Wales), an appeal to the Court of Appeal (England and Wales), and final determination by the Supreme Court of the United Kingdom.

Legal Issues and Arguments

Central legal issues involved the interpretation of patent claims and whether alleged variants fell within the scope of protection, engaging doctrines tied to cases like Catnic Components Ltd v Hill & Smith Ltd and Kirby v. Union Corporation. Parties debated the proper application of the purposive construction approach endorsed in precedents including Improver v. Remington and its compatibility with the doctrine of equivalents as developed in United States and European contexts. Lilly argued for a narrow, literal construction aligning with earlier decisions such as Concentra v. Halliburton-style reasoning, while Actavis relied on arguments echoing Grimme Maschinenfabrik v. Frank-type equivalence analyses and policy considerations cited in writings by scholars affiliated with Cambridge University Press and institutions like the Intellectual Property Office.

Judgment and Reasoning

The Supreme Court of the United Kingdom reversed parts of the Court of Appeal and held that UK law permits a form of the doctrine of equivalents consistent with purposive construction principles from cases including Catnic and Improver. The court set out that infringement can arise where a variant of a claimed invention achieves substantially the same result in substantially the same way as the claimed invention, unless the alleged variant was outside the patentee's monopoly as understood by a person skilled in the art represented by credentials from Imperial College London and King's College London. The judgment, delivered by panels including Lady Hale and Lord Neuberger, reconciled prior authorities and articulated tests drawing on comparative reasoning from European Patent Office practice and decisions from courts such as the Bundesgerichtshof in Germany.

Impact and Significance

The decision reshaped patent enforcement strategies for major corporations like Eli Lilly and Company, Sanofi, AstraZeneca, Johnson & Johnson, and generic firms comparable to Actavis. It prompted revisions to litigation tactics in venues including the High Court of Justice (Chancery Division), adjustments to portfolio management at entities such as Novartis AG and Merck & Co., and influenced policy debates at organizations like the World Intellectual Property Organization and the European Commission. Legal scholarship from faculties at Harvard Law School, Yale Law School, and University College London analysed the ruling's alignment with international patent doctrines and its potential effects on innovation incentives.

Subsequent Developments and Related Litigation

Following the judgment, litigation invoking Actavis principles emerged in cases involving parties such as Pfizer Inc., Bristol-Myers Squibb, Eisai, and Teva Pharmaceutical Industries across jurisdictions including England and Wales, Scotland, and Germany. Appeals and reform proposals were discussed in legislative assemblies like the UK Parliament and referenced in advisory opinions from bodies resembling the Advisory Council on Intellectual Property. Academic commentary continued in journals associated with Oxford University Press and conferences hosted by institutions such as the European Patent Institute and The Royal Society.

Category:United Kingdom patent case law